These were followed by FOENIX-CCA2, which was a multinational, open-label, phase 2 study including 103 patients with advanced iCCA with FGFR2 fusion/rearrangement who had progressed on prior therapy [63]. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.